Abstract: Indazole compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.
Type:
Grant
Filed:
April 26, 2022
Date of Patent:
May 6, 2025
Assignee:
Vanderbilt University
Inventors:
P. Jeffrey Conn, Craig W. Lindsley, Andrew S. Felts, Colleen M. Niswender, Rory A. Capstick, Paul K. Spearing, Sean R. Bollinger
Abstract: The presently-disclosed subject matter includes a compound comprising a first monomer, which is allyl-functionalized and crosslinkable, and a second monomer, which is not crosslinkable. In some embodiments the compounds are photocrosslinkable, and in certain embodiments are photocrosslinkable by ultraviolet light. Also provided are shape memory vascular grafts comprised the of present compounds that can transition from a temporary shape to an original shape when heated above a melting temperature of the graft. Still further provided are methods for treating vascular conditions that utilize embodiments of the present grafts.
Type:
Grant
Filed:
November 12, 2019
Date of Patent:
April 22, 2025
Assignee:
Vanderbilt University
Inventors:
Hak-Joon Sung, Timothy C. Boire, Mukesh K. Gupta, Angela L. Zachman, Sue Hyun Lee, Colleen M. Brophy
Abstract: A method of delivering cells to a target tissue is provided comprising depositing a hydrogel pre-gel comprising magnetic particle-loaded cells to the target tissue and, prior to or during gelation of the hydrogel, drawing the magnetic particle-loaded cells to the tissue with a magnetic field, followed by gelation of the hydrogel to lock the cells in place on the tissue. The cells may be mesenchymal stem cells, such as adipose-derived mesenchymal stem cells, and the target tissue may be adventitial tissue of an aneurysm in a blood vessel. Also provided are devices useful in the method.
Type:
Grant
Filed:
October 18, 2019
Date of Patent:
April 22, 2025
Assignees:
University of Pittsburgh—Of the Commonwealth System of Higher Education, Vanderbilt University
Inventors:
David A. Vorp, Aneesh Krishna Ramaswamy, Justin Sol Weinbaum, Kory James Blose, Timothy Kwang-Joon Chung, Trevor Kickliter, Yogev Baruch, John A. Curci
Abstract: Parallel variable stiffness actuators are disclosed. The parallel variable stiffness actuator can comprise a spring and a variable-stiffness mechanism. The variable-stiffness mechanism can be configured to modulate a stiffness of the parallel variable stiffness actuator. The parallel variable stiffness actuator can further comprise a direct-drive motor arranged in parallel with the spring. A force of the direct-drive motor can be applied directly to a load. Resonant energy accumulation methods implemented by a parallel variable stiffness actuator are also disclosed. A stiffness of a spring can be changed when there is no energy stored by the spring. A resonant energy accumulation method where a force of a direct-drive motor can be applied in resonance with the oscillatory motion, while the stiffness of the parallel variable stiffness actuator can be changed to keep the amplitude of the oscillatory motion nearly constant.
Abstract: Methods of detecting a human leukocyte antigen (HLA)-A*32:01 allele in a subject as disclosed are useful, for example, to determine whether the subject is at risk for developing or has vancomycin-induced drug reaction with eosinophilia and systemic symptoms (DRESS). Methods of treating bacterial infection in a subject with vancomycin-induced DRESS are also disclosed.
Type:
Grant
Filed:
February 14, 2020
Date of Patent:
April 15, 2025
Assignee:
Vanderbilt University
Inventors:
Elizabeth Phillips, Simon Mallal, Katherine Konvinse, Abha Chopra
Abstract: A composite electrode includes two or more types of fibers forming a fiber network, comprising at least a first type of fibers and a second type of fibers. The first type of fibers comprises a first polymer and a first type of particles. The second type of fibers comprises a second polymer and a second type of particles. The second polymer is same as or different from the first polymer. The second type of particles are same as or different from the first type of particles.
Abstract: Systems and methods associated with a phantom assembly are provided. A housing includes a plurality of slots and is formed from a first material having a first appearance under a selected imaging modality. A plurality of inserts are each configured to be received by one of the plurality of slots. At least one insert includes a target formed from a second material having a second appearance under the selected imaging modality, such that the target is readily distinguishable from the housing under the selected imaging modality. The target includes a hollow portion that can be accessed via a removable plug.
Abstract: The present disclosure relates to plasmids, systems, and methods for the transformation of Wolbachia. Disclosed herein are plasmids and systems for use in methods of transforming Wolbachia. The inventors have identified extrachromosomal plasmids within Wolbachia. Disclosed herein is a non-naturally occurring plasmid comprising a nucleic acid encoding a transposase. Disclosed herein is a method for transforming a Wolbachia cell, comprising introducing a non-naturally occurring plasmid into the cell, wherein the plasmid comprises a nucleic acid sequence capable of transforming a Wolbachia cell.
Type:
Grant
Filed:
November 15, 2019
Date of Patent:
March 18, 2025
Assignees:
VANDERBILT UNIVERSITY, THE UNIVERSITY OF CHICAGO
Inventors:
Sarah Bordenstein, Julie Reveillaud, A. Murat Eren, Seth Bordenstein
Abstract: The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.
Abstract: The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.
Abstract: The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amount of compound of the formula and pharmaceutically acceptable salts, solvates, and hydrates thereof to the patient. The variables, e.g. ring A, n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful inhibiting the conversion of glyoxylate to oxalate. When administered to a patient having a disease or disorder associated with elevated oxalate levels, such as PH type 1, type 2, or type 3 or idiopathic hyperoxaluria the compounds prevent or substantially reduce the amount and buildup of oxalate the patient's kidneys, bladder, urinary tract and other parts of the patient's body.
Type:
Grant
Filed:
July 14, 2023
Date of Patent:
February 25, 2025
Assignees:
VANDERBILT UNIVERSITY, THE UAB RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Inventors:
Matthew Hall, Daniel J. Urban, John Knight, Ross Holmes, Kyle David Wood, Alex Waterson, Victor M. Darley-Usmar, Leonard M. Neckers
Abstract: The present disclosure is directed to antibodies binding previously undefined epitopes on influenza A virus hemagglutinin and methods for use thereof.
Abstract: A 2D spatial differentiator operates in transmission and comprises a Si Nano rod photonic crystal that can transform an image, Ein, into its second-order derivative, Eout ??2Ein, allowing for direct discrimination of the edges in the image. The use of a 2D photonic crystal allows for differentiation and edge detection in all directions with a numerical aperture (NA) up to 0.315 and an experimental resolution smaller than 4 ?m. The nanophotonic differentiator is able to be directly integrated into an optical microscope and onto a camera sensor, demonstrating the ease with which it can be vertically integrated into existing imaging systems. Furthermore, integration with a metalens is demonstrated for realizing a compact and monolithic image-processing system. In all cases, the use of the nanophotonic differentiator allows for a significant reduction in size compared to traditional systems, opening new doors for optical analog image processing in applications involving computer vision.
Type:
Grant
Filed:
October 17, 2023
Date of Patent:
February 25, 2025
Assignee:
Vanderbilt University
Inventors:
Jason G. Valentine, You Zhou, Hanyu Zheng
Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof.
Type:
Grant
Filed:
May 1, 2023
Date of Patent:
February 18, 2025
Assignees:
The Trustees of the University of Pennsylvania, The Johns Hopkins University, Vanderbilt University
Inventors:
Drew Weissman, George M. Shaw, Justin R. Bailey, Stuart C. Ray, James Crowe, Jr., Andrew Flyak
Abstract: A fluidic device includes a fluidic chip having a fluidic network comprising a plurality of fluidic channels in fluidic communication with a plurality of input ports, at least one output port, and at least one sensing port; and an actuator configured to engage with the fluidic network to control each fluidic channel to switch between an open state in which fluidic flow through said fluidic channel is permitted and a closed state in which no fluidic flow through said fluidic channel is permitted, so as to selectively collect fluid from multiple inputs via the plurality of input ports, and direct either all of the multiple inputs to the at least one output port, or all but a single selected input to the at least one output port and the single selected input to the at least one sensing port to which an analytical instrument is operably connected.
Type:
Grant
Filed:
July 19, 2021
Date of Patent:
February 4, 2025
Assignee:
VANDERBILT UNIVERSITY
Inventors:
David K. Schaffer, Ronald S. Reiserer, Michael D. Geuy, John P. Wikswo
Abstract: The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof.
Type:
Grant
Filed:
March 18, 2022
Date of Patent:
February 4, 2025
Assignee:
Vanderbilt University
Inventors:
James E. Crowe, Jr., Seth Zost, Robert Carnahan, Pavlo Gilchuk
Abstract: Devices and methods for non-dispersive infrared (NDIR) sensing are disclosed. In one aspect, a non-dispersive infrared sensor is disclosed which, in one embodiment includes a nanophotonic infrared emitting metamaterial (NIREM) emitter configured to selectively emit radiation corresponding to a respective vibrational resonance frequency for each of a plurality of different analytes of interest. The broadband detector can be configured to detect photons associated with vibrational resonance of each of the plurality of analytes of interest in response to the emitted radiation from the NIREM emitter, in order to determine properties of one or more of the analytes of interest.
Type:
Grant
Filed:
January 12, 2023
Date of Patent:
January 28, 2025
Assignees:
Vanderbilt University, Third Floor Materials, Inc.
Inventors:
Joshua D. Caldwell, Edward Sachet, Christopher Shelton, Thomas G. Folland
Abstract: Provided herein are compounds and methods for gene silencing. The compound includes a RNA directly conjugated to an albumin-binding group. The method includes administering a compound comprising a RNA directly conjugated to an albumin-binding group to a subject in need thereof.
Type:
Grant
Filed:
September 14, 2021
Date of Patent:
January 21, 2025
Assignee:
Vanderbilt University
Inventors:
Craig L. Duvall, Samantha M. Sarett, Thomas A. Werfel
Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
Type:
Grant
Filed:
November 4, 2021
Date of Patent:
January 14, 2025
Assignee:
Vanderbilt University
Inventors:
Taekyu Lee, Zhiguo Bian, Johannes Belmar, Plamen P. Christov, Nicholas F. Pelz, Subrata Shaw, Kwangho Kim, James C. Tarr, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik
Abstract: A nasal trans-esophageal echocardiography system includes a nasal trans-esophageal device comprising a sheath defining a lumen therein, the sheath having a width sufficiently narrow to fit through a nasal passage of a subject, an ultrasound probe having a width sufficiently narrow to extend through said lumen defined by said sheath, and a workstation configured to communicate with said ultrasound probe to receive ultrasound signals from said ultrasound probe and to form ultrasound images based on said ultrasound signals.
Type:
Application
Filed:
December 2, 2022
Publication date:
January 9, 2025
Applicants:
The Johns Hopkins University, Vanderbilt University
Inventors:
Ethan TUMARKIN, David ARMSTRONG, Henry R. HALPERIN